SHINE Technologies and Modawina Medical Company (MMC) have entered a strategic distribution partnership to bring Ilumira, SHINE’s non-carrier-added lutetium-177, to patients in the United Arab Emirates, the company announced recently.

“The Middle East represents an exciting growth region for advanced cancer therapies, and we’re proud to help lead that growth,” SHINE CEO and Founder Greg Piefer said in a statement. “What’s most exciting about expanding into the UAE with MMC, a partner with deep relationships with healthcare providers across the region, is the opportunity to deliver breakthrough cancer treatments for patients who may not have had access before.”

According to the agreement, MMC will distribute Ilumira to its extensive network of radiopharmaceutical manufacturers and nuclear medicine centers in the UAE, increasing access to this important cancer-fighting isotope.

Financial terms of the partnership were not disclosed.